RPS6 and melanoma: Consistent with the RNA-Seq and GSEA results (Figure 4, A and B, and Supplemental Figure 3), NR2F1-overexpressing melanoma cells treated with BRAFi + MEKi displayed high mTORC1 pathway readout (phosphorylated S6 [p-S6]) and higher expression of cell-cycle and survival regulators such as cyclin B1, PLK1, p-RB1, p-S6, and Wee1 than did BRAFi + MEKi–treated, non-NR2F1-overexpressing cells (Figure 4C).